Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurobiology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTPRG drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTPRG ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View PTPRG Products |
| Gene Delivery | PTPRG Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformation-preserved cell-based assays. |
View PTPRG Products |
| Benchmark Ab | Anti-PTPRG Recombinant Antibody Recombinant positive control for assay validation. |
View PTPRG Products |
| Validator | PTPRG siRNA Set For knockdown verification and target specificity validation. |
View PTPRG Products |
| Related Target A | CNTN1 Direct extracellular ligand for PTPRG, essential for synaptic adhesion and neuro-oncology signaling. |
View CNTN1 Products |
| Related Target B | PTPRU Closely related receptor tyrosine phosphatase subfamily member for off-target counter-screening. |
View PTPRU Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Subfamily counter-screening (PTPRU/PTPRF) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PTPRG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTPRG therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting specific extracellular domain conformations and ligand-disrupting mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Oncology Biotechs | Solid Tumors, Breast Cancer | Internalization Assay (Need high-purity ECD-Fc) |
| Bispecific | Immunotherapy Developers | Neuro-oncology, Glioblastoma | Heterodimer Validation (Need Cross-reactive Abs) |
| Small Molecule | Kinase/Phosphatase Specialists | Myeloproliferative Neoplasms | Selectivity Assay (Need Mutant vs WT Proteins) |